Abstract:Objective:To investigate the value of postoperative radiotherapy in patients with cT 1-2N 1M 0 breast cancer after neoadjuvant chemotherapy and modified radical mastectomy which postoperative pathology showed that the number of axillary lymph node metastases was 0-3. Methods:One hundred and twenty-eight patients diagnosed with cT 1-2N 1M 0 breast cancer admitted to our hospital from January 1, 2000 to December 31, 2014 were retrospectively reviewed. All patients underwent neoadjuvant chemotherapy and modified radical mastectomy. The number of postoperative axillary lymph node metastases was 0-3. According to whether there was postoperative radiotherapy or not, the whole group of patients was divided into radiotherapy group ( n=87) and non-radiotherapy group ( n=41). In the two groups after operation, there were 43 and 11 patients with 1-3 axillary lymph node metastases (ypN 1), while there were 44 and 30 patients without axillary lymph node metastases (ypN 0) respectively. The 5-year locoregional recurrence-free survival (LRFS) rate, disease-free survival (DFS) rate and overall survival (OS) rate were calculated by Kaplan-Meier method, and the differences were compared by log-rank test. Univariate analysis was performed to analyze the effects of clinical features and treatment on prognosis. Results:The 5-year LRFS rate, DFS rate and OS rate of 128 patients were 91.4%, 82.8% and 93.0% respectively. The 5-year LRFS rates of the patients in the radiotherapy group and the non-radiotherapy group were 94.3% and 85.4% respectively, and the difference was not statistically significant ( χ2=3.055, P=0.080). As well as the 5-year DFS rates were 89.7% and 68.3% respectively, and the difference was statistically significant ( χ2=9.312, P=0.005). The 5-year OS rates were 94.3% and 90.2% respectively, and the difference was not statistically significant ( χ2=0.810, P=0.368). In the subgroup analysis, the 5-year LRFS rates of the patients who had achieved ypN 1 in the radiotherapy group and the non-radiotherapy group were 93.0% and 72.7%, and the 5-year DFS rates were 88.4% and 63.6%, with statistically significant differences ( χ2=4.248, P=0.039; χ2=4.525, P=0.033). The 5-year OS rates were 90.7% and 81.8% respectively, and the difference was not statistically significant ( χ2=0.713, P=0.399). The 5-year LRFS rates of the patients who had achieved ypN 0 in the radiotherapy group and the non-radiotherapy group were 95.5% and 90.0% respectively, with no statistically significant difference ( χ2=0.872, P=0.350). The 5-year DFS rates were 90.9% and 70.0% respectively, with statistically significant difference ( χ2=5.439, P=0.019). The 5-year OS rates were 97.7% and 93.3% respectively, with no statistically significant difference ( χ2=0.876, P=0.349). The univariate analysis indicated that age ( χ2=11.709, P=0.001) and blood vessel invasion ( χ2=7.608, P=0.006) were significant influencing factors for 5-year LRFS rate. Postoperative radiotherapy ( χ2=9.312, P=0.002) was a prognostic factor for 5-year DFS rate. Age ( χ2=6.093, P=0.014) and hormone receptor status ( χ2=3.974, P=0.046) were prognostic factors for OS. Conclusion:For the cT 1-2N 1M 0 breast cancer patients with 1-3 positive axillary lymph nodes after neoadjuvant chemotherapy, postmastectomy radiotherapy has local control benefit, and it can improve DFS. However, the benefit of postoperative radiotherapy needs to be further investigated in patients with pathological negative axillary lymph nodes after neoadjuvant chemotherapy.

Positive metastasis axillary lymph nodes after radical mastectomy for breast cancer as an indication of postoperative radiotherapy

Indications for Postmastectomy Radiotherapy in Breast Cancer Patients with 1 -3 Positive Axillary Nodes

Prognostic Factors of Early Breast Cancer Treated with Radiation after Radical Mastectomy

Role of Number of Sentinel Nodes in Predicting Non-Sentinel Node Metastasis in Breast Cancer

The Role of Postmastectomy Radiotherapy in Breast Cancer Patients with T1-T2 and One to Three Positive Axillary Nodes

Survival Analysis of Postmastectomy Radiotherapy for Breast Cancer Staged in Ct 1-2N 1M 0 after Neoadjuvant Chemotherapy with 0-3 Metastatic Lymph Nodes

Abstract P4-11-22: The Role of Postmastectomy Radiation in Breast Cancer Patients with One to Three Positive Axillary Lymph Nodes

Number of Negative Lymph Nodes Can Predict Survival after Postmastectomy Radiotherapy According to Different Breast Cancer Subtypes.

The Role of Postmastectomy Radiotherapy in Different Molecular Subtypes of Breast Cancer Patients with T 1 - T 2 and One to Three Positive Axillary Nodes

Value of Postmasteetomy Radiotherapy in T_2 Breast Cancer Patients with 1-3 Positive Axillary Lymph Nodes

Role of radiotherapy and prognostic factors in breast cancer patients at high-risk of recurrence trea-ted with modified radical mastectomy and chemotherapy

Postmastectomy locoregional recurrence and survival in early stage breast cancer patients with one to three axillary lymph node metastases]

The Value of Lymph Node Ratio in the Prediction of Rectal Cancer Patient Survival after Preoperative Chemoradiotherapy.

Post-operative Radiotherapy is Beneficial for T1/T2 Triple Negative Breast Cancer Patients with Four or More Positive Lymph Nodes.

Meta-analysis on survival rate after post-mastectomy radiotherapy for breast cancer patients with T1-T2 and 1-3 positive lymph nodes

Number of negative lymph nodes can predict survival of breast cancer patients with four or more positive lymph nodes after postmastectomy radiotherapy

The value of radiotherapy in patients with T1-2 N1 M0 triple-negative breast cancer after modified radical mastecomy

Post-mastectomy Radiotherapy Can Improve Survival in Breast Cancer Patients Aged 35 Years or Younger with Four or More Positive Nodes but Not in One to Three Positive Nodes

Radiotherapy for and Prognosis of Breast Cancer Patients with Local-Regional Recurrence after Mastectomy

Radiotherapeutic Management of Regional Lymph Nodes Recurrence Following Mastectomy

Establishment of a risk scoring system for predicting locoregional recurrence in T1 to T2 node-negative breast cancer patients treated with mastectomy: Implications for postoperative radiotherapy.